Yttrium-90 radiation segmentectomy of oligometastatic urothelial carcinoma.

Andrew E Warfield, Geoffrey M Scriver, Joshua Kallen, Alan R Massouh, Anant D Bhave, Bill S Majdalany

Abstract readCase Reports

In one paragraph

Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrew E WarfieldDepartment of Radiology, Division of Interventional Radiology, University of VT Medical Center, Burlington, VT, USA.

Geoffrey M ScriverDepartment of Radiology, Division of Interventional Radiology, University of VT Medical Center, Burlington, VT, USA.

Joshua KallenDepartment of Radiology, Division of Interventional Radiology, University of VT Medical Center, Burlington, VT, USA.

Alan R MassouhDepartment of Radiology, Division of Interventional Radiology, University of VT Medical Center, Burlington, VT, USA.

Anant D BhaveDepartment of Radiology, Division of Interventional Radiology, University of VT Medical Center, Burlington, VT, USA.

Bill S MajdalanyDepartment of Radiology, Division of Interventional Radiology, University of VT Medical Center, Burlington, VT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many patients with primary or metastatic liver tumors are not surgical candidates or have lesions that are not amenable to thermal ablation. Radiation segmentectomy involves microcatheter delivery of an ablative dose of Yttrium-90 microspheres through arteries feeding hepatic malignancy. This treatment is performed with curative intent in hepatocellular carcinoma and has shown promising results in various hepatic metastases. However, many studies have paired radiation segmentectomy with systemic chemotherapy. This case report describes the outcomes of a chemotherapy naïve patient with urothelial carcinoma and oligometastatic spread to the liver treated with Yttrium-90 radiation segmentectomy (Y90RS). Initial treatment achieved disease control of metastasis until imaging at 15 months revealed local recurrence which was treated with repeat Y90RS. Throughout treatment, the patient remained at her functional baseline with normal labs and independence in activities of daily living.

Indexed as

Hepatic metastasesRadiation segmentectomyRadioembolizationUrothelial carcinomaY90

Identifiers

PMID41458048

DOI10.1016/j.radcr.2025.11.035

PMCPMC12741286

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.